Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review

Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review

Migraine is a chronic and disabling disorder affecting >1 billion individuals worldwide. Current treatments for the prevention of migraine include antihypertensives, antiepileptics, and antidepressants, and all share limited tolerability and adherence, highlighting the need for the development o...

Full description

Bibliographic Details
Main Authors: Theodoros Mavridis, Chrysa Koniari, Nikolaos Fakas, Dimos D. Mitsikostas
Format: Article
Language:English
Published: European Medical Journal 2019-01-01
Series:European Medical Journal Innovations
Subjects:
adverse events (ae)
calcitonin gene-related peptide (cgrp)
eptinezumab
erenumab
fremanezumab
galcanezumab
headache
migraine
monoclonal antibodies (mab)
Online Access:https://www.emjreviews.com/innovations/article/anti-calcitonin-gene-related-peptide-monoclonal-antibodies-adverse-effects-what-do-we-really-know-a-literature-review/

Internet

https://www.emjreviews.com/innovations/article/anti-calcitonin-gene-related-peptide-monoclonal-antibodies-adverse-effects-what-do-we-really-know-a-literature-review/

Similar Items